HonCode

Go Back   HER2 Support Group Forums > her2group
Register Gallery FAQ Members List Calendar Today's Posts

Reply
 
Thread Tools Display Modes
Old 01-11-2007, 07:07 PM   #1
sunny Lisa
Member
 
Join Date: Nov 2006
Location: Florida
Posts: 14
Question Herceptin for noninvasive CA?/trial?

Hi All, Has anyone heard of receiving Herceptin when nodes are neg. and no microinvasion was found? I had a 9cm toumor (DCIS insitu) removed by mastectomy and left with positive margins. I will start radiation but I would feel better if I had some systemic treatment to prevent reoccurence. I am ER neg. so Tamoxafin is out or may help minimally?
Has anyone else been in this situation and if so what were your treatment options? Are there any clinical trials? Thanks, Lisa
sunny Lisa is offline   Reply With Quote
Old 01-12-2007, 09:24 AM   #2
Lani
Senior Member
 
Join Date: Mar 2006
Posts: 4,778
Clinical trial of herceptin+radiation therapy for ER- her2+ DCIS at MD Anderson

1: Breast J. 2007 Jan-Feb;13(1):72-5.
Novel clinical trial designs for treatment of ductal carcinoma in situ of the breast with trastuzumab (herceptin).

Gonzalez RJ,
Buzdar AU,
Fraser Symmans W,
Yen TW,
Broglio KR,
Lucci A,
Esteva FJ,
Yin G,
Kuerer HM.
Department of Surgical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.
Because ductal carcinoma in situ (DCIS) avidly expresses Her2/neu, the target of the monoclonal antibody trastuzumab, and because trastuzumab has been shown to be effective against invasive breast cancer, trastuzumab may be effective for reducing the tumor burden and abrogating or reversing the hypothesized transition from in situ to invasive disease in patients with DCIS. To test this hypothesis, a trial of neoadjuvant trastuzumab for DCIS has been opened at our institution. Because trastuzumab has been shown to act as a radiosensitizing agent for Her2/neu-overexpressing cancer and because there are currently no systemic treatments for estrogen-receptor-negative DCIS, it makes sense to investigate whether use of trastuzumab concurrently with postoperative radiation therapy improves local control of DCIS. The National Surgical Adjuvant Breast and Bowel Project (NSABP) is planning a trial to test this hypothesis. The risk of cardiac toxicity associated with the doses of trastuzumab planned for these trials (cumulative doses of 8 mg/kg for our trial and 14 mg/kg in the NSABP trial) is believed to be minimal, but the safety profile of these approaches will need to be closely monitored.
PMID: 17214797 [PubMed - in process]
Lani is offline   Reply With Quote
Old 01-12-2007, 09:50 PM   #3
Bev
Senior Member
 
Join Date: Dec 2005
Location: Alexandria, VA
Posts: 1,055
Lisa, See if you can get an oncotype dx test paid for. Then get 2nd opinions. I would think doing Herceptin would be a good choice. BB
Bev is offline   Reply With Quote
Old 01-13-2007, 09:39 AM   #4
sunny Lisa
Member
 
Join Date: Nov 2006
Location: Florida
Posts: 14
second opinion/margins

Thank you both for the good info. I will be getting a second opinion from Dr Elisabeth McKeen in West Palm Beach. Mayo clinic in Jacksonville said no to Herceptin and my local oncologist just thought it was absurd but it seems to be the only choice. I found out my margins were very positive, CA still in the deep margins. Lisa
sunny Lisa is offline   Reply With Quote
Reply


Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off

Forum Jump


All times are GMT -7. The time now is 08:47 AM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter